Myeloproliferative disordersLEVINE, Ross L; GILLILAND, D. Gary.Blood. 2008, Vol 112, Num 6, pp 2190-2198, issn 0006-4971, 9 p.Article

Role of Additional Novel Therapies in Myeloproliferative NeoplasmsFISKUS, Warren; GANGULY, Siddhartha; KAMBHAMPATI, Suman et al.Hematology/oncology clinics of North America. 2012, Vol 26, Num 5, issn 0889-8588, vii, 959-980 [22 p.]Article

Transient myeloproliferative disorderMOIZ, Bushra; SHAFLQ, Maria.Blood. 2012, Vol 120, Num 24, issn 0006-4971, p. 4672Article

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative diseaseAGARWAL, Anupriya; BUMM, Thomas G. P; DEININGER, Michael W et al.Blood. 2008, Vol 112, Num 5, pp 1960-1970, issn 0006-4971, 11 p.Article

Myeloproliferative neoplasmsPUBLICOVER, Amy; MEDD, Patrick.Clinical medicine. 2013, Vol 13, Num 2, pp 188-192, issn 1470-2118, 5 p.Article

Possible new LNK mutations in myeloproliferative neoplasmsHA, Jung-Sook; JEON, Dong-Seok.American journal of hematology. 2011, Vol 86, Num 10, pp 866-868, issn 0361-8609, 3 p.Article

Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment StrategiesTEFFERI, Ayalew; VAINCHENKER, William.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 573-582, issn 0732-183X, 10 p.Article

Blood cell activation in myeloproliferative neoplasmsCERVANTES, Francisco; ARELLANO-RODRIGO, Eduardo; ALVAREZ-LARRAN, Alberto et al.Haematologica (Roma). 2009, Vol 94, Num 11, pp 1484-1488, issn 0390-6078, 5 p.Article

Molecular basis of myelodysplastic/myeloproliferative neoplasmsREITER, Andreas; INVERNIZZI, Rosangela; CROSS, Nicholas C. P et al.Haematologica (Roma). 2009, Vol 94, Num 12, pp 1634-1638, issn 0390-6078, 5 p.Article

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesABDEL-WAHAB, Omar; MULLALLY, Ann; HUBERMAN, Kety et al.Blood. 2009, Vol 114, Num 1, pp 144-147, issn 0006-4971, 4 p.Article

Myeloproliferative Neoplasm Animal ModelsMULLALLY, Ann; LANE, Steven W; BRUMME, Kristina et al.Hematology/oncology clinics of North America. 2012, Vol 26, Num 5, issn 0889-8588, viii-ix, 1065-1081 [18 p.]Article

DNMT3A mutations in myeloproliferative neoplasmsSTEGELMANN, F; BULLINGER, L; SCHLENK, R. F et al.Leukemia. 2011, Vol 25, Num 7, pp 1217-1219, issn 0887-6924, 3 p.Article

Myeloproliferative Disorders in PregnancyHARRISON, Claire N; ROBINSON, Susan E.Hematology/oncology clinics of North America. 2011, Vol 25, Num 2, issn 0889-8588, vii, 261-275 [16 p.]Article

Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid NeoplasmsOGAWA, Seishi; SHIH, Lee-Yung; SUZUKI, Takahiro et al.Clinical cancer research (Print). 2010, Vol 16, Num 15, pp 3825-3831, issn 1078-0432, 7 p.Article

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsQUINTAS-CARDAMA, Alfonso; VADDI, Kris; RUPAR, Mark et al.Blood. 2010, Vol 115, Num 15, pp 3109-3117, issn 0006-4971, 9 p.Article

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsSCORE, Joannah; HIDALGO-CURTIS, Claire; CHASE, Andrew et al.Blood. 2012, Vol 119, Num 5, pp 1208-1213, issn 0006-4971, 6 p.Article

Competing cell clones in myeloproliferative neoplasmAL-KALI, Aref; VERSTOVSEK, Srdan; KANTARJIAN, Hagop et al.Blood. 2010, Vol 116, Num 23, pp 5074-5075, issn 0006-4971, 2 p.Article

Myeloproliferative Disorders and the Hyperviscosity SyndromeADAMS, Bruce D; BAKER, Russell; LOPEZ, J. Abraham et al.Hematology/oncology clinics of North America. 2010, Vol 24, Num 3, issn 0889-8588, viii, 585-602 [28 p.]Article

Myeloproliferative Disorders and the Hyperviscosity SyndromeADAMS, Bruce D; BAKER, Russell; LOPEZ, J. Abraham et al.Emergency medicine clinics of North America. 2009, Vol 27, Num 3, issn 0733-8627, vi, 459-476 [19 p.]Article

Genotype-Phenotype Interactions in the Myeloproliferative NeoplasmsGODFREY, Anna L; GREEN, Anthony R.Hematology/oncology clinics of North America. 2012, Vol 26, Num 5, issn 0889-8588, vii, 993-1015 [23 p.]Article

Disordered Signaling in Myeloproliferative NeoplasmsANAND, Shubha; HUNTLY, Brian J. P.Hematology/oncology clinics of North America. 2012, Vol 26, Num 5, issn 0889-8588, vii-viii, 1017-1035 [20 p.]Article

RECONNAITRE, CLASSER ET TRAITER LES SYNDROMES MYÉLOPROLIFÉRATIFS BCR-ABL NÉGATIFSKNOOPS, L.Louvain médical. 2008, Vol 127, Num 7, pp 247-255, issn 0024-6956, 9 p.Conference Paper

Polyglobulie de Vaquez et mutation JAK-2 chez l'enfant : à propos d'une observation = Polycythemia vera and JAK-2 mutation in childhood : a case reportBRACONNIER, O; MONPOUX, F; AFFANETTI, M et al.Archives de pédiatrie (Paris). 2007, Vol 14, Num 10, pp 1202-1205, issn 0929-693X, 4 p.Article

Prise en charge diagnostique et thérapeutique d'un patient porteur d'une thrombocytose = Investigation and management of patients presenting with thrombocytosisCHEMINANT, M; DELARUE, R.La Revue de médecine interne (Paris). 2013, Vol 34, Num 8, pp 465-471, issn 0248-8663, 7 p.Article

Two Clinical Phenotypes in Polycythemia VeraSPIVAK, Jerry L; CONSIDINE, Michael; WILLIAMS, Donna M et al.The New England journal of medicine. 2014, Vol 371, Num 9, pp 808-817, issn 0028-4793, 10 p.Article